more

BeiGene (BGNE)

(Delayed Data from NSDQ)

$162.25 USD

+0.24 (0.15%)

Updated May 3, 2024 04:00 PM ET

After-Market: $161.91 -0.34 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum D VGM

Industry Rank:

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View

by Zacks Equity Research Published on August 12,2019

Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.

Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates

by Zacks Equity Research Published on August 12,2019

Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.

biotechs

AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

by Zacks Equity Research Published on August 08,2019

AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

by Zacks Equity Research Published on August 08,2019

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y

by Zacks Equity Research Published on August 08,2019

PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.

Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies

by Zacks Equity Research Published on August 07,2019

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

Why Earnings Season Could Be Great for BeiGene (BGNE)

by Zacks Equity Research Published on August 07,2019

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BGNEPositive Net Change

ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on August 06,2019

On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.

medical

Can Pharmacy Services Drive CVS Health's (CVS) Q2 Earnings?

by Zacks Equity Research Published on August 05,2019

Akin to the previous quarters, net new business and the steady uptake of Maintenance Choice programs are likely to bolster CVS Health's (CVS) PBM business in Q2.

Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018

by Zacks Equity Research Published on March 01,2019

Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.

pharmaceuticals

Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4

by Zacks Equity Research Published on March 01,2019

Intrexon (XON) incurs narrower-than-expected loss in the fourth quarter of 2018.

BGNEPositive Net Change

pharmaceuticals

Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat

by Zacks Equity Research Published on February 28,2019

Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.

BGNEPositive Net Change

pharmaceuticals

BeiGene, Ltd. (BGNE) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research Published on February 18,2019

BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.